Welcome to Markets Desk, here's what's moving the conversation today.
GitLab is giving the software sector something to chew on after posting twenty-one point three percent revenue growth and beating earnings estimates in its second fiscal quarter of two thousand twenty seven. The company raised its full-year adjusted earnings guidance, crediting a flexible consumption pricing model that's converting developer demand into real, recurring revenue. That's a meaningful signal for enterprise software investors watching AI monetization plays.
Shifting to biotech, Viking Therapeutics continues to trade well below consensus Wall Street price targets, and the gap is drawing attention from both sides of the trade. The bull case rests on significant pipeline upside, but skeptics are pushing back, questioning whether the market is pricing in execution risk that optimistic targets simply aren't accounting for. Worth watching closely.
And on the insider buying front, Resideo Technologies saw a senior vice president step in with a direct purchase of nearly eleven thousand shares, valued at roughly two hundred twenty-six thousand dollars. Insider buying at that scale rarely happens without conviction, and in a market where executives are often sellers, this kind of direct purchase tends to catch institutional eyes.
That's the tape. Markets Desk, signing off the floor.
